Translational
Neurodegeneration

Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer's disease

Mari Aksnes[1*] , Hans Christian D. Aass[2], Ann Tiiman[3], Trine Holt Edwin[4,5,6], Lars Terenius[3], Nenad Bogdanović[7], Vladana Vukojević[3] and Anne-Brita Knapskog[4]

Abstract

Background: The aggregation of amyloid β (Aβ) is central in the pathogenesis of Alzheimer's disease (AD). Recently it has been shown that specifically, larger, Thioflavin T-binding Aβ aggregates are associated with increased neuroinflammation and cytokine release. This study was aimed to quantify fibrillary amyloid aggregates, so-called nanoplaques, and investigate their relationship with cytokines in the cerebrospinal fluid (CSF).

Methods: CSF was collected from 111 patients assessed for cognitive complaints at the Oslo University Hospital Memory Clinic. The patients were grouped based on their amyloid status. The CSF nanoplaque concentration was quantified with the Thioflavin T-fluorescence correlation spectroscopy (ThT-FCS) assay. The levels of nine cytokines (eotaxin-1, granulocyte stimulating factor, interleukin [IL]-6, IL-7, IL-8, monocyte chemoattractant protein-1, gamma-induced protein 10, macrophage inflammatory protein [MIP]-1α, and MIP-1β) were quantified with a magnetic bead-based multiplex assay and read on a Luminex IS 200 instrument.

Results: There were 49 amyloid-negative and 62 amyloid-positive patients in the cohort; none of the cytokines differed significantly between the amyloid groups. The increased nanoplaque levels were associated with levels of MIP-1β below the lower limit of quantification, and with decreased levels of MIP-1α and IL-8. The associations remained significant when adjusted for age, sex, cognitive function, apolipoprotein ε4 status and CSF core biomarker levels.

Conclusion: The cytokine levels were not associated with amyloid status in this cohort. The nanoplaque levels were negatively associated with MIP-1β, MIP-1α and IL-8, which is in line with recent findings suggesting that the upregulation of some cytokine markers has a protective role and is negatively associated with AD progression.

Keywords: Alzheimer's disease, Amyloid, Amyloid beta peptides, Amyloidogenic proteins, Biomarkers, Cerebrospinal fluid, Cytokines, Inflammation, Fluorescence correlation spectroscopy, Thioflavin T

* Correspondence: mari.aksnes@medisin.uio.no
[1]Department of Geriatric Medicine, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
Full list of author information is available at the end of the article

Background

Alzheimer's disease (AD) is the leading cause of dementia globally. This neurodegenerative disorder is characterised by extracellular amyloid β (Aβ) deposits, intracellular tau neurofibrillary tangles and pervasive synaptic loss [1]. These neuropathological changes precede the onset of clinical dementia by years or decades [2, 3]. The primary cause of sporadic AD is unknown, but it is hypothesised that the accumulation of Aβ aggregates is the initial trigger [4]. In addition, increasing evidence has linked neuroinflammation to AD pathogenesis, particularly amyloid pathology [5]. Astrocytes and microglia, immune cells of the brain, cluster around Aβ aggregates.

Activated astrocytes and microglia release cytokines, which are signalling proteins with both pro- and anti-inflammatory effects [5]. In AD, this causes a self-propagating inflammatory cycle where Aβ aggregates continually activate microglia, provoking the release of cytokines, which in turn affect Aβ production and aggravate the plaque formation [5, 6]. As such, cytokines are upregulated early in the Aβ-induced inflammatory process, and are interesting biomarkers for AD [7]. Several cytokines have been found to differentiate AD patients from patients with mild cognitive impairment (MCI) or cognitively unimpaired controls [8], but inconsistent results are common. In addition, investigations of the relationship between established markers of AD neuropathology such as cerebrospinal fluid (CSF) $A\beta_{42}$ and cytokines have resulted in inconsistent findings [9–11].

Importantly, Aβ aggregates are not uniform, and range from small oligomers to larger protofibrils and fibrils [12, 13]. The aggregates vary in size and molecular structure, which results in different mechanisms of toxicity. Recently, cell culture investigations have shown that while smaller soluble aggregates exert neurotoxicity by increasing the cell membrane permeability, larger protofibrils that can bind Thioflavin T increase neuroinflammation and cytokine release from glial cells [14, 15]. Moreover, such fibrillar aggregates appear to contribute to neuroinflammation by increasing the blood-brain barrier permeability in vitro [16]. Of note, it has been shown that longer, inflammation-inducing amyloid fibrils are increased in AD CSF compared to the CSF from MCI patients and healthy controls [14]. However, the relationship between these fibrils and other biomarkers has not been established. It would be of interest to extend research on fibrillary amyloid aggregates and inflammatory markers in cell cultures to clinical samples. This highlights the importance of quantifying different Aβ species as AD biomarkers. Indeed, whereas the established enzyme-linked immunosorbent $A\beta_{42}$ assays primarily recognise monomeric Aβ, the Thioflavin T-fluorescence correlation spectroscopy (ThT-FCS)

assay quantifies structured amyloidogenic aggregates, so-called nanoplaques, with high specificity [17–19]. As such, the relationship between ThT-FCS-labelled nanoplaques and markers of neuroinflammation, such as cytokines, should be explored.

In the current study, we set out to investigate the relationship between CSF nanoplaque levels and nine cytokines in a memory clinic cohort, including both patients with AD pathology and patients with non-AD disorders.

Methods

Memory clinic cohort

One hundred and eleven patients from the Norwegian Registry of Persons Assessed for Cognitive Symptoms (NorCog), who were assessed at the Oslo University Hospital Memory Clinic, were included in this study. The patients were included in NorCog between June 2014 and November 2018.

Clinical assessment

The patients were assessed according to an established research protocol [20]. The patients completed a battery of standardised cognitive tests [20], including the Mini-Mental State Examination (MMSE), and also underwent a physical examination, including blood sampling, lumbar puncture, apolipoprotein E (APOE) genotyping, magnetic resonance imaging (MRI, $n = 107$), ^{18}F-FDG positron emission tomography (PET, $n = 65$) and ^{18}F-flutemetamol PET ($n = 54$) brain scans. The core CSF biomarkers for AD were analysed for all patients ($n = 111$) at the Department of Interdisciplinary Laboratory Medicine and Medical Biochemistry at Akershus University Hospital with enzyme-linked immunosorbent assays using the Innotest kit (Innogenetics, Ghent, Belgium). Cognitive and functional impairment on the Clinical Dementia Rating (CDR) scale were scored post-hoc by experienced CDR raters (ABK and THE). The CDR sum-of-boxes (CDR-SOB), which has been found to accurately separate MCI and dementia [21], was used in the analyses.

Clinical diagnoses were made post-hoc by experienced memory clinicians (ABK and THE). Subjective cognitive decline (SCD) was diagnosed according to the Subjective Cognitive Decline Initiative-criteria [22], whilst MCI and dementia were diagnosed using the core clinical criteria of the National Institute of Aging and the Alzheimer's Association (NIA-AA) [23, 24]. Clinical diagnoses of MCI-AD, AD-dementia and AD-dementia aetiologically mixed presentation, collectively Alzheimer's clinical syndrome, were made following the NIA-AA diagnostic criteria [23, 24]. These diagnoses were primarily based on clinical presentation, however, in the case of MCI patients with atypical or mixed presentations, biomarker data were consulted and patients with negative

biomarker data were considered non-AD. Together with the SCD patients, the patients diagnosed with vascular dementia [25], frontotemporal dementia [26], and MCI not caused by AD were considered as clinically non-AD.

AT(N) classification
In line with the 2018 NIA-AA research framework, patients were categorised based on three groups of biomarker data: A – reflecting Aβ pathology, T – reflecting tau pathology and N – reflecting neurodegeneration [27]. The patients were classified according to the AT(N) status based on all available biomarkers: CSF $A\beta_{42}$ and/or ^{18}F-flutemetamol results for A; CSF phosphorylated tau (P-tau) for T; and CSF total tau (T-tau), ^{18}F-FDG PET and/or MRI results for N. The ^{18}F-flutemetamol PET scans were visually classified as amyloid-positive or negative according to a validated electronic image reader programme [28]. The FDG PET and MRI scans were also visually classified for signs of neurodegeneration [29, 30]. For the CSF biomarkers, the following cut-off values were applied for a normal test: $A\beta_{42} >$ 700 pg/ml, P-tau < 80 pg/ml, and T-tau < 300 pg/ml for those < 50 years, < 450 pg/ml for those aged 50–70 years and < 500 pg/ml for those > 70 years [31]. In the case of the presence of disparity among the biomarkers in one group, the patient was classified as positive. In the statistical analyses, patients were categorised based exclusively on amyloid status (A+/A- groups).

Analysis of CSF nanoplaque levels
The ThT-FCS assay procedure has been described in detail by Tiiman et al. [19]. Briefly, 1.6 μL of 2.5 mM ThT in deionised water was mixed with 200 μL of CSF. Fluctuations in fluorescence intensity were recorded in duplicates using the ConfoCor3 system (Carl Zeiss, Jena, Germany) [32]. Signals were collected in 30 series of 10 × 10 s measurements (total measurement time 3000 s). Automated analysis of fluorescence intensity fluctuations and detection of bursts in fluorescence intensity that reflect the passage of ThT-positive nanoplaques through the observation volume element, were performed offline using a dedicated software written in MATLAB (The MathWorks, Inc., Natick, MA) by Tiiman et al. [19]. A burst was identified and denoted a "single event" if the increase in fluorescence intensity was at least five times larger than the standard deviation of the whole time series. The total number of single events per hour, i.e. the frequency of single events per hour (fSEO), directly reflects the concentration of nanoplaques in the CSF.

Analysis of cytokines
All CSF samples underwent analysis of cytokines using a custom-made nine-plex kit (Cat No. 12014058, Bio-Rad Laboratories, Hercules, CA) containing eotaxin-1, granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-6, IL-7, IL-8, interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein (MIP)-1α, and MIP-1β. The nine cytokines were selected based on a screening of a representative set of samples with the human cytokine 27 plex kit (Cat No. M500KCAF0Y, Bio-Rad Laboratories). A 10% bovine serum albumin (Cat No. A5403-50G, lot SLBL9495V, Sigma Aldrich, St. Louis, MO) solution in PBS (pH 7.4, Gibco Cat No. 10010–015, lot 2062123, Thermo Fisher Scientific, Waltham, MA) was added to all CSF samples to a final concentration of 0.5% and vortexed. Then the samples were centrifuged at 10 000×g for 10 min at 4 °C and 50 μL of the supernatant was loaded onto the assay plate. The CSF cytokine levels were measured on a Luminex IS 200 instrument (Bio-Rad). An in-house control was used to observe both intra percentage coefficient of variation and longitudinal (inter) percentage coefficient of variation. Cytokine concentrations below the lower limit of quantification (LLOQ) or above the upper limit of quantification extrapolated by the analysis software were also included in the statistical analysis.

Statistical analysis
Group differences were assessed by parametric (t-test) or non-parametric (Mann-Whitney test) test depending on the data distribution. As the distributions of CSF nanoplaque levels and most of the cytokines were markedly right-skewed, the results are presented as medians and quartiles. The correlation analyses were reported with Spearman's ρ correlation coefficient. Bonferroni-corrected P-values are presented for the correlations between nanoplaque levels and cytokines. Significant associations between nanoplaque levels and cytokines were further explored in multiple linear regression analyses adjusted for sex, age, CDR-SOB and APOE ε4 carrier status (Model 1), and biomarkers CSF $A\beta_{42}$ and CSF P-tau (Model 2). The natural logarithm transformed nanoplaque variable log (fSEO) was used in the regression analysis in order to achieve normally distributed standardised residuals. Statistical analyses were conducted with STATA 15.1 (StataCorp, College Station, TX) and R 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria).

Results
Patient characteristics are presented in Table 1. The A+ and A- groups differed significantly in all variables except the years of education (P = 0.34). In the A+ group, 28 patients (45%) were T+ and 58 patients (94%) were N+, whereas in the A- group, 8 patients (16%) were T+ and 31 patients (63%) were N+. The clinical diagnosis

Table 1 Demographic and clinical characteristics for all patients and by amyloid group

	All ($n = 111$)	A- ($n = 49$)	A+ ($n = 62$)	P
Number of women/men	57/54	20/29	37/25	0.05
Age in years	65.0 (8.4)	61.4 (8.9)	67.8 (6.8)	< 0.01
Years of education	13.8 (3.6)	14.2 (3.4)	13.5 (3.7)	0.34
MMSE*	25.7 (4.1)	27.1 (3.0)	24.6 (4.4)	< 0.01
CDR-SOB*	3.3 (2.4)	2.6 (2.3)	3.9 (2.3)	< 0.01
APOE ε4*, n (%)	63 (57.8)	17 (35.4)	46 (75.4)	< 0.01
Clinical diagnosis				< 0.01
Clinical non-AD	48 (43.2)	41 (83.7)	7 (11.3)	
Alzheimer's clinical syndrome	63 (56.8)	8 (16.3)	55 (88.7)	
Stage, n (%)				< 0.01
SCD	11 (9.9)	9 (18.4)	2 (3.2)	
MCI	42 (37.8)	27 (55.1)	15 (24.2)	
Dementia	58 (52.3)	13 (26.5)	45 (72.6)	
CSF Aβ$_{42}$ pg/ml	777.3 (353.8)	1110.6 (231.1)	513.9 (154.8)	< 0.01
CSF T-tau pg/ml	500.2 (367.9)	336.9 (167.5)	629.2 (428.5)	< 0.01
CSF P-tau pg/ml	71.7 (39.9)	55.7 (22.3)	84.3 (46.0)	< 0.01
CSF nanoplaques, median (Q1;Q3)	15 (11.4; 21.6)	13.2 (10.8; 17.4)	18 (12; 24.6)	0.02[†]

Data are given as mean (standard deviation) and P values are for two-tailed *t*-tests (continous variables) or χ^2-tests (categorical variables) comparing amyloid groups, unless otherwise indicated

Aβ amyloid-β, *AD* Alzheimer's disease, *APOE* apolipoprotein E, *CDR-SOB* Clinical Dementia Rating Scale Sum of Boxes, *CSF* cerebrospinal fluid, *MCI* mild cognitive impairment, *MMSE* Mini-Mental State Examination, *n* number of patients, *P-tau* phosphorylated tau, *Q* quartile, *SCD* subjective cognitive decline, *T-tau* total tau
*MMSE, n = 104; CDR-SOB, n = 108; APOE, n = 109, † *P*-value for Mann-Whitney U test

was consistent with the amyloid status: 89% of the A+ patients had Alzheimer's clinical syndrome, and 84% of the A- patients had clinical non-AD.

The CSF Aβ$_{42}$ levels were negatively associated with the levels of CSF nanoplaques ($\rho = -0.20$, $P = 0.04$), CSF T-tau ($\rho = -0.39$, $P < 0.001$) and CSF P-tau ($\rho = -0.30$, $P = 0.001$). Moreover, the levels of CSF P-tau and CSF T-tau were strongly correlated with each other ($\rho = 0.94$, $P < 0.001$). The CSF nanoplaque levels were not associated with CSF P-tau ($\rho = 0.001$) or CSF T-tau ($\rho = -0.01$), $P > 0.05$.

Detectability of cytokines
The markers eotaxin-1, IL-8, MCP-1 and IP-10 were detectable in all patient CSF samples. In a minority of samples, the levels of G-CSF ($n = 4$, 3.6%), IL-6 ($n = 1$, 0.9%) and MIP-1α ($n = 1$, 0.9%) were below the LLOQ, and therefore included as zero. In the majority of samples, the levels of MIP-1β ($n = 77$, 68.8%) and IL-7 ($n = 71$, 63.4%) were below the LLOQ, so MIP-1β and IL-7 were dichotomised as detectable/not detectable.

Cytokine levels between amyloid groups
The CSF levels of cytokines are presented in Table 2. There were no significant differences in the levels of cytokines or the detectability of the dichotomised markers between the amyloid groups ($P > 0.05$).

Cytokine and nanoplaque levels
The distributions of nanoplaque levels in the patients with non-detectable/detectable levels of MIP-1β and IL-7 are presented in Fig. 1. The nanoplaque levels were increased among patients with non-detectable levels of MIP-1β (median = 16.5, inter-quartile range: 12.6; 24) compared to those with detectable levels of MIP-1β (median = 12.6, inter-quartile range: 9.6; 18.6, $P = 0.01$). There was no difference in the nanoplaque levels between those with non-detectable levels of IL-7 (median = 15, inter-quartile range: 11.4; 22.2) and those with detectable levels of IL-7 (median = 15.3, inter-quartile range: 10.95; 21, $P = 0.73$).

The nanoplaque levels were negatively associated with IL-8 ($\rho = -0.34$, $P = 0.007$) and MIP-1α levels ($\rho = -0.38$, $P = 0.001$), but not associated with any of the other cytokines (Fig. 2).

The negative association between IL-8 and nanoplaque levels remained significant when adjusting for the covariates sex, age, cognitive function and *APOE* ε4 carrier status ($P = 0.001$), and for Aβ$_{42}$ and P-tau levels ($P = 0.003$) in two regression models (Table 3). None of the covariates were significantly associated with IL-8.

Similarly, the negative association between MIP-1α and nanoplaque levels remained significant when adjusting for the covariates sex, age, cognitive function and *APOE* ε4 carrier status ($P = 0.001$) and for Aβ$_{42}$ and P-

Table 2 CSF cytokine levels for all patients and by amyloid group

|	All (n = 111)	A- (n = 49)	A+ (n = 62)	P
Continuous markers (pg/mL), median (Q1; Q3)[a]				
Eotaxin-1	3.95 (3.27; 4.72)	3.93 (3.48; 4.72)	3.97 (3.16; 4.49)	0.73
G-CSF	15.75 (6.37; 27.94)	11.79 (5.16; 29.2)	16.24 (8.33; 25.91)	0.46
IL-6	1.51 (1.00; 2.31)	1.44 (1.09; 2.45)	1.54 (1.00; 2.06)	0.58
IL-8	20.59 (17.58; 25.44)	20.58 (18.11; 25.12)	20.66 (17.33; 25.44)	0.54
IP-10	1740 (1333; 2196)	1845 (1333; 2205)	1652 (1342; 2118)	0.49
MCP-1	153.87 (127.44; 177.55)	142.39 (127.44; 177.34)	154.64 (129.57; 177.72)	0.61
MIP-1α	0.33 (0.2; 0.42)	0.31 (0.17; 0.40)	0.34 (0.23; 0.49)	0.10
Dichotomised markers, n (% detected)[b]				
MIP-1β	34 (30.63)	16 (32.65)	18 (29.03)	0.68
IL-7	40 (36.04)	17 (34.69)	23 (37.10)	0.79

G-CSF granulocyte colony-stimulating factor, *IL* interleukin, *IP* interferon gamma-induced protein, *MCP* monocyte chemoattractant protein, *MIP* macrophage inflammatory protein, *n* number of patients, *Q* quartile
[a]Two-tailed Mann-Whitney U test was used for group comparisons, [b]χ^2-test was used for group comparisons

tau levels ($P = 0.002$) in the two regression models (Table 3). In the first model (Model 1, Table 3), increased age significantly predicted increased MIP-1α levels, with a 0.05 pg/ml increase of MIP-1α levels for each 10-year increase of age ($P = 0.006$). In the second model (Model 2, Table 3), age remained a significant predictor for increased MIP-1α and the increased levels of P-tau were associated with increased levels of MIP-1α, with a 10 pg/ml increase in P-tau predicting a 0.014 pg/ml increase in MIP-1α levels ($P < 0.001$). The decreased nanoplaque levels were the strongest predictor for increased MIP-1α levels in both models.

Discussion

There has been mounting evidence suggesting that inflammatory mediators released by microglia and astrocytes, such as cytokines, contribute to AD neuropathology [5]. Amyloid pathology has been linked to increased neuroinflammation; in vitro ThT-reactive amyloid aggregates have been specifically shown to induce cytokine release [15]. In this study, we used the ThT-FCS assay to quantify ThT-reactive amyloidogenic aggregates (nanoplaques) in the CSF of memory clinic patients. For the first time, we investigated the association between these nanoplaques and CSF cytokine levels, and had two main findings: first, three cytokines


Fig. 1 Distribution of nanoplaque levels in relation to MIP-1β and IL-7 detectability. Purple dots indicate A+ patients, green dots indicate A- patients; darker colours indicate overlapping values

Fig. 2 The associations between CSF nanoplaques and cytokine levels. **a** Spearman correlation matrix for all cytokines and CSF nanoplaque levels. **b** Scatter plots of CSF nanoplaque levels versus each of the cytokines. Note the broken abscissa for IL-6 (middle) and IP-10 (bottom left). Purple dots indicate A+ patients, green dots indicate A- patients; darker colours indicate overlapping values. There was no significant difference in cytokine levels between the A+ and A- patients

were negatively associated with CSF nanoplaque levels, and second, the CSF cytokine levels did not differ between amyloid-positive and amyloid-negative patients.

It has been hypothesised that larger amyloid protofibrils in the CSF of AD patients cause an increase in inflammation [14]. The nanoplaques quantified by the ThT-FCS assay include both protofibrils and other ThT-reactive amyloid aggregates composed of > 40 monomers. However, in the current study, the CSF nanoplaque levels were negatively associated with the CSF levels of IL-8, MIP-1α and MIP-1β. While we have previously shown that the CSF nanoplaque levels are negatively associated with CSF Aβ42 [33], the association between nanoplaques and these cytokines appears independent of the CSF Aβ42 and P-tau levels. Although amyloid aggregates have been shown to increase the release of cytokines [14, 15], this finding is in line with recent research showing that the up-regulation of several cytokines, including G-CSF and MIP-

1β, is negatively associated with AD disease progression and may have a neuroprotective role [34]. As such, it is possible that the higher level of cytokines interferes with the formation of nanoplaques, and that nanoplaque levels increase when cytokine levels are downregulated.

Indeed, the inflammatory activity in AD is complex and may change across disease stages. It has been proposed that there are two peaks of inflammatory (microglial) activity in AD: an early, potentially neuroprotective peak, and a later, neurotoxic peak [35]. In line with the two-peak hypothesis, a recent longitudinal PET study has demonstrated a biphasic trajectory of cortical inflammation in early AD [36]: over a two-year period, microglial activation increased in MCI patients who converted from amyloid-negative to amyloid-positive, but in MCI patients who were amyloid positive at baseline, the cortical inflammation decreased as amyloid levels plateaued. Furthermore, this study also showed that

Table 3 Adjusted associations between nanoplaque levels and IL-8 and MIP-1α

	Model 1		Model 2	
	β-coefficient (CI)	*P*	β-coefficient (CI)	*P*
Dependent variable: IL-8 pg/ml				
CSF nanoplaques[a]	−3.830 (−6.038; −1.622)	0.001	−3.536 (−5.821; −1.250)	0.003
Male sex	−0.802 (−3.376; 1.773)	0.538	−1.071 (−3.682; 1.540)	0.418
Age	−0.054 (−0.214; 0.106)	0.505	−0.029 (−0.203; 0.144)	0.737
CDR-SOB	0.170 (−0.390; 0.731)	0.548	0.144 (−0.431; 0.720)	0.620
APOE ε4	−0.452 (−1.818; 0.915)	0.513	−0.373 (−1.799; 1.054)	0.605
CSF Aβ$_{42}$ pg/ml			0.002 (−0.002; 0.007)	0.321
CSF P-tau pg/ml			0.018 (−0.015; 0.052)	0.285
Dependent variable: MIP-1α pg/ml				
CSF nanoplaques[a]	−0.083 (−0.133; −0.034)	0.001	−0.079 (−0.127; −0.031)	0.002
Male sex	0.049 (−0.010; 0.107)	0.101	0.037 (−0.018; 0.092)	0.180
Age	0.005 (0.002; 0.009)	0.006	0.005 (0.001; 0.009)	0.009
CDR-SOB	0.012 (−0.001; 0.025)	0.064	0.007 (−0.005; 0.019)	0.233
APOE ε4	0.030 (−0.001; 0.061)	0.058	0.023 (−0.007; 0.053)	0.128
CSF Aβ$_{42}$ pg/ml			0.000 (−0.000; 0.000)	0.486
CSF P-tau pg/ml			0.001 (0.001; 0.002)	< 0.001

Aβ amyloid-β, *APOE* apolipoprotein E, *CI* confidence interval, *CDR-SOB* Clinical Dementia Rating Scale Sum of Boxes, *CSF* cerebrospinal fluid, *f*$_{SEO}$ frequency of single event occurrence per hour, *IL-8* interleukin-8, *MIP-1α* macrophage inflammatory protein 1α, *P-tau* phosphorylated tau

[a]Log (*f*$_{SEO}$). The β-coefficient denotes the degree of change in the dependent variable (IL-8 or MIP-1α) for a one-step change in the continuous predictor variables or the presence of the dichotomised predictor variables

inflammation increased with the increasing tangle load in amyloid-positive patients with tau pathology at baseline [36]. As the nanoplaque levels are a measure of amyloid aggregation that is not correlated with amyloid-PET [17], it would be of interest to follow the relationship between nanoplaques and inflammatory markers in longitudinal studies.

In the central nervous system, cytokines can be produced by microglia, astrocytes and neurons. In vitro, microglia, astrocytes and neurons have been shown to release IL-8 in response to other pro-inflammatory cytokines such as IL-1β [37, 38]. Similarly, MIP-1α and MIP-1β appear to be expressed by both microglia and astrocytes. In microglial cell cultures, expression of MIP-1α and MIP-1β is increased in response to fibrillary Aβ [39]. However, in animal models of AD, MIP-1α production appears to be driven by astrocytes [40]. In the AD brain, MIP-1β is expressed by a subpopulation of astrocytes (together with IP-10) [41]. Moreover, eotaxin-1 is released by astrocytes [42]; G-CSF is expressed by neurons [43], whereas IL-6 and IL-7 appear to be primarily expressed by microglia [44, 45]. As a consequence of these complex interactions in neuroinflammation, it is uncertain what proportion of the measured cytokines is derived from which source.

Inflammatory markers have been extensively studied as biomarkers for AD, both in the CSF and in peripheral samples [46, 47]. A recent meta-analysis of 170 studies

has found that several markers clearly differ between AD/MCI patients and healthy controls [8]. However, in this study we did not include healthy controls, but rather compared amyloid-positive patients to memory clinic patients without amyloid pathology, including patients with other dementias. Importantly, neuroinflammation is a shared feature of several neurodegenerative disorders including AD, frontotemporal dementia, Parkinson's disease, dementia with Lewy bodies and vascular dementia [34, 48, 49], and several cytokines are similarly altered in AD versus frontotemporal dementia [34, 50, 51] or vascular dementia [49, 52]. The overlap between these different neurodegenerative disorders could explain why there was no difference in cytokine levels between the amyloid-positive and amyloid-negative groups in this study. Moreover, in this study the included patients were classified based exclusively on their amyloid status. Different approaches to classification and diagnoses are an important source of conflicting results in the literature [53]. Some research on the inflammatory markers in biomarker-defined groups has been restricted to amyloid-positive patients [14, 54]. Unfortunately, this precludes the comparison of amyloid-positive and amyloid-negative patients with cognitive disorders. However, one recent publication including both amyloid-positive and amyloid-negative patients demonstrated that the increased CSF cytokine levels were dependent on the abnormal tau and/or neurodegeneration

Aksnes *et al. Translational Neurodegeneration*   (2021) 10:18

Page 8 of 10

biomarkers, while the cytokine levels were not increased in patients with isolated amyloid pathology [53]. Of note, in the current cohort the majority of patients in both amyloid groups had abnormal tau and/or neurodegeneration markers, which could explain the lack of group differences.

The current study was strengthened by the inclusion of a comprehensively characterised memory clinic cohort with extensive clinical and biological data, including multiple biomarker measurements and *APOE*-genotyping. By including other disease controls rather than cognitively healthy controls, this study can inform on the overlapping inflammatory mechanisms across different disorders and the use of inflammatory markers, or rather lack thereof, in differential diagnosis of memory clinic patients. A further strength is the application of the highly sensitive ThT-FCS assay. The ThT-FCS assay has the ultimate sensitivity and permits the detection of single aggregated particles in small sample volumes, within a wide range of molecular concentrations. This is achieved without the use of signal-amplification, protein separation or immune probes.

The current study has several limitations. First, the ThT-FCS method cannot identify the amino acid sequence of the polypeptides in the nanoplaques: ThT selectively binds aggregates with a β-sheet secondary structure. In addition to Aβ, several other proteins can aggregate to this structure and bind ThT [55, 56]. Therefore, the nanoplaques detected may not be composed exclusively of aggregated Aβ. Second, the sample size was limited, which restricted subgroup analyses. Third, this study did not include a healthy control group. Therefore, the relationship between nanoplaques and cytokines in the CSF of cognitively healthy individuals remains unknown; the level of cytokines in the absence of amyloid pathology may be below the detection threshold. Finally, the cross-sectional design of this study precluded the monitoring of the relationship between nanoplaques and cytokines over time. This is especially relevant given the apparent biphasic nature of cytokines in AD, and longitudinal studies are required.

Future research should assess whether the nanoplaques and cytokines are also associated in serum samples. Moreover, studies on microvascular pathology, a common feature of AD [57], are another avenue for future research: MIP-1α receptors are highly expressed on brain microvessels and it has been hypothesised that MIP-1α binding could affect angiogenesis and blood-brain barrier permeability [58–60]. IL-8 has also been linked to angiogenesis and blood-brain barrier dysfunction [61, 62]. As larger Aβ aggregates have been shown to contribute to neuroinflammation by compromising the blood-brain barrier [16], the relationship of markers of blood-brain barrier integrity with nanoplaque levels and cytokines in CSF and serum would be of interest.

Conclusions

In conclusion, this study suggests a negative relationship between CSF amyloidogenic nanoplaques and cytokines MIP-1β, MIP-1α and IL-8. This finding contrasts with in vitro studies that have shown increased inflammation in response to aggregated amyloid from the CSF. However, the direction of this association is in line with recent evidence suggesting a protective role of the upregulation of certain cytokines. The relationship between nanoplaques and inflammatory markers should be further explored across the different stages of the AD pathophysiological process, in order to inform on the dynamics between aggregated amyloid and inflammation through the disease.

levels are available upon reasonable request to the authors. All data availability is dependent on the approval from the REC South East, contact at e-mail: post@helseforskning.etikkom.no.

Declarations

Ethics approval and consent to participate
All patients and their family caregivers gave their informed, written consent for participation. This study was approved by the Norwegian Regional Committees for Medical and Health Research Ethics (REC South East, 2017/2235 and 2017/371) and the Data Protector Officer at Oslo University Hospital.

Consent for publication
Not applicable.

Competing interests
ABK and THE have worked on clinical trials for Roche (BN29553) and Boehringer-Ingelheim (1346.0023). AT, LT and VV have filed a patent application under the Patent Cooperation Treat (PCT): WO 2019/192969 A1 "Method for the Diagnosis of Amyloid-Associated Diseases". HCDA, MA and NB declared they had no competing interests.

Author details
[1]Department of Geriatric Medicine, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. [2]Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway. [3]Department of Clinical Neurosciences (CNS), Center for Molecular Medicine CMM L8:01, Karolinska Institutet, Stockholm, Sweden. [4]Department of Geriatric Medicine, The Memory Clinic, Oslo University Hospital, Oslo, Norway. [5]Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway. [6]Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway. [7]Department of Neurobiology, Care Science and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden.

References
1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1: a006189.
2. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207–16.
3. Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain. 2015;138(10):2814–33. https://doi.org/10.1093/brain/awv236.
4. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595–608. https://doi.org/10.15252/emmm.201606210.
5. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4): 388–405. https://doi.org/10.1016/S1474-4422(15)70016-5.
6. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP [V717I] transgenic mice. J Neuroinflammation. 2005;2(1):22. https://doi.org/10.1186/1742-2094-2-22.
7. Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med. 2015;3:136.
8. Shen XN, Niu LD, Wang YJ, Cao XP, Liu Q, Tan L, et al. Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019;90(5): 590–8. https://doi.org/10.1136/jnnp-2018-319148.
9. Hesse R, Wahler A, Gummert P, Kirschmer S, Otto M, Tumani H, et al. Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β. BMC Neurol. 2016;16(1):185. https://doi.org/10.1186/s12883-016-0707-z.
10. Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91(9):e867–e77. https://doi.org/10.1212/WNL.0000000000006082.
11. Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S, et al. Cerebrospinal fluid and plasma levels of inflammation differentially relate to CNS markers of Alzheimer's disease pathology and neuronal damage. J Alzheimers Dis. 2018;62(1):385–97. https://doi.org/10.3233/JAD-170602.
12. Nag S, Sarkar B, Bandyopadhyay A, Sahoo B, Sreenivasan VKA, Kombrabail M, et al. Nature of the amyloid-beta monomer and the monomer-oligomer equilibrium. J Biol Chem. 2011;286(16):13827–33. https://doi.org/10.1074/jbc.M110.199885.
13. Finder VH, Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis. 2007;4(1):13–27. https://doi.org/10.1159/000100355.
14. De S, Whiten DR, Ruggeri FS, Hughes C, Rodrigues M, Sideris DI, et al. Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. Acta Neuropathol Commun. 2019;7(1):120. https://doi.org/10.1186/s40478-019-0777-4.
15. De S, Wirthensohn DC, Flagmeier P, Hughes C, Aprile FA, Ruggeri FS, et al. Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms. Nat Commun. 2019;10(1):1541. https://doi.org/10.1038/s41467-019-09477-3.
16. Parodi-Rullán R, Ghiso J, Cabrera E, Rostagno A, Fossati S. Alzheimer's amyloid β heterogeneous species differentially affect brain endothelial cell viability, blood-brain barrier integrity, and angiogenesis. Aging Cell. 2020;19: e13258.
17. Aksnes M, Müller EG, Tiiman A, Edwin TH, Terenius L, Revheim ME, et al. Amyloidogenic nanoplaques in cerebrospinal fluid: relationship to amyloid brain uptake and clinical Alzheimer's disease in a memory clinic cohort. J Alzheimers Dis. 2020;77(2):831–42. https://doi.org/10.3233/JAD-200237.
18. Tiiman A, Jarvet J, Graslund A, Vukojevic V. Heterogeneity and turnover of intermediates during amyloid-beta (Abeta) peptide aggregation studied by fluorescence correlation spectroscopy. Biochemistry. 2015;54(49):7203–11. https://doi.org/10.1021/acs.biochem.5b00976.
19. Tiiman A, Jelic V, Jarvet J, Jaremo P, Bogdanovic N, Rigler R, et al. Amyloidogenic nanoplaques in blood serum of patients with Alzheimer's disease revealed by time-resolved thioflavin T fluorescence intensity fluctuation analysis. J Alzheimers Dis. 2019;68(2):571–82. https://doi.org/10.3233/JAD-181144.
20. Braekhus A, Ulstein I, Wyller TB, Engedal K. The Memory Clinic--outpatient assessment when dementia is suspected. Tidsskr Nor Laegeforen. 2011; 131(22):2254–7. https://doi.org/10.4045/tidsskr.11.0786.
21. O'Bryant SE, Lacritz LH, Hall J, Waring SC, Chan W, Khodr ZG, et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the National Alzheimer's Coordinating Center Database. Arch Neurol. 2010;67(6):746–9. https://doi.org/10.1001/archneurol.2010.115.
22. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10(6):844–52. https://doi.org/10.1016/j.jalz.2014.01.001.
23. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270–9. https://doi.org/10.1016/j.jalz.2011.03.008.
24. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263–9. https://doi.org/10.1016/j.jalz.2011.03.005.
25. Sachdev P, Kalaria R, O'Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206–18. https://doi.org/10.1097/WAD.0000000000000034.
26. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456–77. https://doi.org/10.1093/brain/awr179.

27. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018.

28. Buckley CJ, Sherwin PF, Smith APL, Wolber J, Weick SM, Brooks DJ. Validation of an electronic image reader training programme for interpretation of [18F] flutemetamol β-amyloid PET brain images. Nucl Med Commun. 2017;38(3):234–41. https://doi.org/10.1097/MNM.0000000000000633.

29. Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36(12):2103–10. https://doi.org/10.1007/s00259-009-1264-0.

30. Ferreira D, Cavallin L, Larsson EM, Muehlboeck JS, Mecocci P, Vellas B, et al. Practical cut-offs for visual rating scales of medial temporal, frontal and posterior atrophy in Alzheimer's disease and mild cognitive impairment. J Intern Med. 2015;278(3):277–90. https://doi.org/10.1111/joim.12358.

31. Kalheim LF, Fladby T, Coello C, Bjørnerud A, Selnes P. [18F]-Flutemetamol uptake in cortex and white matter: comparison with cerebrospinal fluid biomarkers and [18F]-fludeoxyglucose. J Alzheimers Dis. 2018;62(4):1595–607. https://doi.org/10.3233/JAD-170582.

32. Vukojevic V, Heidkamp M, Ming Y, Johansson B, Terenius L, Rigler R. Quantitative single-molecule imaging by confocal laser scanning microscopy. Proc Natl Acad Sci U S A. 2008;105(47):18176–81. https://doi.org/10.1073/pnas.0809250105.

33. Aksnes M, Tiiman A, Edwin TH, Terenius L, Bogdanović N, Vukojević V, et al. Comparison of cerebrospinal fluid amyloidogenic nanoplaques with core biomarkers of Alzheimer's disease. Front Aging Neurosci. 2021;12. https://doi.org/10.3389/fnagi.2020.608628.

34. Taipa R, das Neves SP, Sousa AL, Fernandes J, Pinto C, Correia AP, et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline. Neurobiol Aging. 2019;76:125–32. https://doi.org/10.1016/j.neurobiolaging.2018.12.019.

35. Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer's disease trajectory. Brain. 2017;140(3):792–803. https://doi.org/10.1093/brain/aww349.

36. Ismail R, Parbo P, Madsen LS, Hansen AK, Hansen KV, Schaldemose JL, et al. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study. J Neuroinflammation. 2020;17(1):151. https://doi.org/10.1186/s12974-020-01820-6.

37. Nagai A, Nakagawa E, Hatori K, Choi HB, McLarnon JG, Lee MA, et al. Generation and characterization of immortalized human microglial cell lines: expression of cytokines and chemokines. Neurobiol Dis. 2001;8(6):1057–68. https://doi.org/10.1006/nbdi.2001.0437.

38. Du S-H, Zhang W, Yue X, Luo X-Q, Tan X-H, Liu C, et al. Role of CXCR1 and interleukin-8 in methamphetamine-induced neuronal apoptosis. Front Cell Neurosci. 2018;12. https://doi.org/10.3389/fncel.2018.00230.

39. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, et al. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197(12):1657–66. https://doi.org/10.1084/jem.20021546.

40. Martin E, Boucher C, Fontaine B, Delarasse C. Distinct inflammatory phenotypes of microglia and monocyte-derived macrophages in Alzheimer's disease models: effects of aging and amyloid pathology. Aging Cell. 2017;16(1):27–38. https://doi.org/10.1111/acel.12522.

41. Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol. 2000;108(1-2):227–35. https://doi.org/10.1016/S0165-5728(00)00285-X.

42. Ivanovska M, Abdi Z, Murdjeva M, Macedo D, Maes A, Maes M. CCL-11 or Eotaxin-1: an immune marker for ageing and accelerated ageing in neuro-psychiatric disorders. Pharmaceuticals (Basel). 2020;13(9). https://doi.org/10.3390/ph13090230.

43. Schneider A, Krüger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005;115(8):2083–98. https://doi.org/10.1172/JCI23559.

44. Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 1863;2016:1218–27.

45. Jana M, Mondal S, Jana A, Pahan K. Interleukin-12 (IL-12), but not IL-23, induces the expression of IL-7 in microglia and macrophages: implications for multiple sclerosis. Immunology. 2014;141(4):549–63. https://doi.org/10.1111/imm.12214.

46. Bagyinszky E, Giau VV, Shim K, Suk K, An SSA, Kim S. Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis. J Neurol Sci. 2017;376:242–54. https://doi.org/10.1016/j.jns.2017.03.031.

47. Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol. 2014;50(2):534–44. https://doi.org/10.1007/s12035-014-8657-1.

48. Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Immunol. 2018;9:2122.

49. Angelopoulos P, Agouridaki H, Vaiopoulos H, Siskou E, Doutsou K, Costa V, et al. Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci. 2008;118(12):1659–72. https://doi.org/10.1080/00207450701392068.

50. Rentzos M, Paraskevas GP, Kapaki E, Nikolaou C, Zoga M, Rombos A, et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J Neurol Sci. 2006;249(2):110–4. https://doi.org/10.1016/j.jns.2006.05.063.

51. Rentzos M, Zoga M, Paraskevas GP, Kapaki E, Rombos A, Nikolaou C, et al. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J Geriatr Psychiatry Neurol. 2006;19(2):114–7. https://doi.org/10.1177/0891988706286226.

52. Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett. 2005;383(1-2):12–6. https://doi.org/10.1016/j.neulet.2005.03.051.

53. Rauchmann BS, Sadlon A, Perneczky R. Soluble TREM2 and inflammatory proteins in Alzheimer's disease cerebrospinal fluid. J Alzheimers Dis. 2020;73(4):1615–26. https://doi.org/10.3233/JAD-191120.

54. Motta C, Finardi A, Toniolo S, Di Lorenzo F, Scaricamazza E, Loizzo S, et al. Protective role of cerebrospinal fluid inflammatory cytokines in patients with amnestic mild cognitive impairment and early Alzheimer's disease carrying apolipoprotein E4 genotype. J Alzheimers Dis. 2020;76(2):681–9. https://doi.org/10.3233/JAD-191250.

55. Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21(10):1332–40. https://doi.org/10.1038/s41593-018-0235-9.

56. Xue C, Lin TY, Chang D, Guo Z. Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R Soc Open Sci. 2017;4(1):160696. https://doi.org/10.1098/rsos.160696.

57. Steinman J, Sun HS, Feng ZP. Microvascular alterations in Alzheimer's disease. Front Cell Neurosci. 2020;14:618986.

58. Tripathy D, Thirumangalakudi L, Grammas P. Expression of macrophage inflammatory protein 1-alpha is elevated in Alzheimer's vessels and is regulated by oxidative stress. J Alzheimers Dis. 2007;11(4):447–55. https://doi.org/10.3233/JAD-2007-11405.

59. Andjelkovic AV, Pachter JS. Characterization of binding sites for chemokines MCP-1 and MIP-1α on human brain microvessels. J Neurochem. 2000;75(5):1898–906. https://doi.org/10.1046/j.1471-4159.2000.0751898.x.

60. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, et al. Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging. 2007;28(4):485–96. https://doi.org/10.1016/j.neurobiolaging.2006.02.013.

61. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology. 2005;7(2):122–33. https://doi.org/10.1215/S1152851704001061.

62. Kossmann T, Stahel PF, Lenzlinger PM, Redl H, Dubs RW, Trentz O, et al. Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production. J Cereb Blood Flow Metab. 1997;17(3):280–9. https://doi.org/10.1097/00004647-199703000-00005.